Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

Autor: Joan Morote, Emilio Esteban, L A San José, Miriam Mendez, C de la Piedra, A García-Escudero, A Murias, Cristina Meseguer, M. Unda, B González-Gragera, C González-Enguita, M Constela, E. Solsona, Comet-Batlle J, A G del Alba, J M Martínez-Javaloyas, A Lassa, J.M. Fernandez, Gustavo Rubio, E. Sánchez, Antonio Alcaraz, Ana Mañas, P Samper, Angel Tabernero, Maria J. Ribal, V Calderero, C Quicios, Juan Antonio Virizuela, Marta Martín-Fernández, Joaquim Bellmunt, Urbano Anido, Antonio Gómez-Caamaño, J A Contreras, Ignacio Mahillo-Fernández, Gaspar Reynés, Joan Carles, J Segarra, Daniel U. Campos Delgado, Federico Vazquez, F Gómez-Veiga, P C Lara, Bárbara Rodríguez, Jose Luis Alvarez-Ossorio

Publikováno v: BRITISH JOURNAL OF CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
British Journal of Cancer
Biblos-e Archivo. Repositorio Institucional de la UAM

Background: Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases, biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in thes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7169fda3b70cd9ab44e2b9b802bc8e9d
https://doi.org/10.1038/bjc.2013.270